Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Orlistat

Fatty acid synthase inhibitor
 
ALX-350-152-M050 50 mg 47.00 USD
 
ALX-350-152-M250 250 mg 132.00 USD
Do you need bulk/larger quantities?
 
Cell permeable, irreversible inhibitor of gastric and pancreatic lipases. Shows only minimal activity against amylase, trypsin, chymotrypsin, or phospholipase A2 (PLA2). Partially inhibits the hydrolysis of triglycerides and lowers the absorption of dietary fat and promotes weight loss. Anti-obesity drug. Exhibits antitumor activity by inhibition of the thioesterase domain of fatty acid synthase (FAS) both in vitro and in vivo.

Product Specification

Alternative Name:Tetrahydrolipstatin, N-Formyl-L-leucine-(1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester
 
Formula:C29H53NO5
 
MW:495.7
 
Source:Synthetic. Originally isolated from Streptomyces sp.
 
CAS:96829-58-2
 
MI:14: 6869
 
Purity:≥97%
 
Appearance:White to off-white solid.
 
Solubility:Soluble in DMSO or 100% ethanol.
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
Use/Stability:Stock solutions are stable for up to 6 weeks when stored at -20°C.
 
Handling:Protect from light and moisture. After reconstitution, prepare aliquots and store at -20°C.
 
350-152
Please mouse over
350-152

Product Literature References

Orlistat and sibutramine beyond weight loss: E. Mannucci, et al.; Nutr. Metab. Cardiovasc. Dis. 70, 1228 (2008), Abstract;
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene: J.A. Menendez, et al.; Ann. Oncol. 16, 1253 (2005), Abstract;
Differential uptake of subfractions of triglyceride-rich lipoproteins by THP-1 macrophages: A.M. Palmer, et al.; Atherosclerosis 180, 233 (2005), Abstract;
A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2: L.M. Knowles, et al.; J. Biol. Chem. 279, 30540 (2004), Abstract; Full Text
Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity: S.J. Kridel, et al.; Cancer Res. 64, 2070 (2004), Abstract;
Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine: B. Sternby, et al.; Clin. Nutr. 21, 395 (2002), Abstract;
Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat): A. Lookene, et al.; Eur. J. Biochem. 222, 395 (1994), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
Fatty acid synthase
By biological activity:
Fatty acid synthase Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,